Laboratory of Experimental Immunology and Immunotherapy, Nikolaus-Fiebiger-Centre for Molecular Medicine, Medical Department III, University of Erlangen-Nuernberg, Erlangen, Germany.
Clin Exp Immunol. 2010 May;160(2):161-7. doi: 10.1111/j.1365-2249.2009.04081.x. Epub 2009 Dec 16.
Immunoglobulin G (IgG) molecules can have two completely opposite functions. On one hand, they induce proinflammatory responses and recruit innate immune effector cells during infection with pathogenic microorganisms or autoimmune disease. On the other hand, intravenous infusion of high doses of pooled IgG molecules from thousands of donors [intravenous IG (IVIG) therapy] represents an efficient anti-inflammatory treatment for many autoimmune diseases. Whereas our understanding of the mechanism of the proinflammatory activity of IgG is quite advanced, we are only at the very beginning to comprehend how the anti-inflammatory activity comes about and what cellular and molecular players are involved in this activity. This review will summarize our current knowledge and focus upon the two major models of either IVIG-mediated competition for IgG-triggered effector functions or IVIG-mediated adjustment of cellular activation thresholds used to explain the mechanism of the anti-inflammatory activity.
免疫球蛋白 G(IgG)分子可以具有两种完全相反的功能。一方面,它们在感染致病性微生物或自身免疫性疾病时会引发炎症反应并募集先天免疫效应细胞。另一方面,静脉输注来自数千供体的高剂量 IgG 分子(静脉内免疫球蛋白 [IVIG] 治疗)是许多自身免疫性疾病的有效抗炎治疗方法。虽然我们对 IgG 促炎活性的机制有了相当深入的了解,但我们才刚刚开始理解抗炎活性是如何产生的,以及涉及该活性的细胞和分子参与者有哪些。这篇综述将总结我们目前的知识,并重点介绍 IVIG 介导的 IgG 触发效应功能竞争或 IVIG 介导的细胞激活阈值调整这两种主要模型,以解释抗炎活性的机制。